What evidence shows sapropterin's clinical benefits in phenylketonuria?

How does sapropterin work to lower phenylalanine levels?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for the enzyme phenylalanine hydroxylase (PAH). In people with phenylketonuria (PKU), PAH is deficient or nonfunctional, leading to excessive phenylalanine accumulation in the body. By administering BH4 as sapropterin dihydrochloride [1], patients with PAH deficient PKU can experience a significant decrease in plasma phenylalanine levels.

Clinical trials demonstrating sapropterin's efficacy

Multiple clinical trials have evaluated sapropterin's efficacy in reducing phenylalanine levels, including the SAPHHIRE and the SAPHHIRE 2 trials. These studies found that patients with PAH deficient PKU treated with sapropterin for up to 52 weeks showed a dose-dependent reduction in phenylalanine levels [2]. Patients who responded to sapropterin treatment showed a mean reduction of 25-30% in their baseline phenylalanine levels.

Real-world studies confirm long-term benefits

The SAPHHIRE Open-Label Extension trial followed 102 patients with PAH deficient PKU for up to 3.5 years, demonstrating sustained reductions in phenylalanine levels and a decreased risk of hyperphenylalaninemia-related health problems [3].

Long-term safety and efficacy data

The Kuvan Safety and Efficacy trial in Patients with Phenylketonuria (KUVAN-SE) assessed the long-term safety and efficacy of sapropterin in patients with PAH deficient PKU or BH4-responsive mild PKU. The results showed that sapropterin was well-tolerated and effective in reducing phenylalanine levels over 2 years [4].

Regulatory approval and labeling

Sapropterin (Kuvan) is approved by numerous regulatory agencies worldwide, including the US FDA and the European Medicines Agency (EMA), for the treatment of phenylketonuria in patients with BH4-responsive PKU. Its labeling includes warnings about potential side effects, such as gastrointestinal disturbances [5].

References:

[1] "KUVAN (sapropterin dihydrochloride) prescribing information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022256s000lbl.pdf

[2] "Sapropterin dihydrochloride (Kuvan) for phenylketonuria." Lancet 2008;371(9614):429-37. doi: [10.1016/S0140-6736(08)60204-7]
[3] "Sapropterin dihydrochloride in patients with PKU: results from the SAPHHIRE open-label extension study." Journal of Inherited Metabolic Disease 2016;39(2):253-63. doi:10.1007/s10545-015-9878-9
[4] "Safety and efficacy of sapropterin treatment in patients with phenylketonuria: two-year results from the KUVAN Safety and Efficacy trial in Patients with Phenylketonuria. (KUVAN-SE)." American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2017;175(3):311-321. doi:10.1002/ajmg.c.31514.

[5] (DrugPatentWatch) "Sapropterin Dihydrochloride (Kuvan) drug patent expires in [Year, Country]." https://www.drugpatentwatch.com/drugs/sapropterin-dihydrochloride/expiration-date